| Literature DB >> 15887967 |
Carmen Dominguez1, Lourdes Prieto, Matthew J Valli, Steven M Massey, Mark Bures, Rebecca A Wright, Bryan G Johnson, Sherri L Andis, Ann Kingston, Darryle D Schoepp, James A Monn.
Abstract
LY354740 (1) is a highly potent and selective agonist of metabotropic glutamate (mGlu) receptors 2 and 3. In the present study, we have prepared C3- and C4-methyl-substituted variants of rac-1, compounds 5, 9, and 13. Each of these racemic methyl-substituted analogues displaced specific binding of the mGlu2/3 receptor antagonist (3)H-2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid ((3)H-LY341495) from membranes expressing mGlu2 or mGlu3 receptor subtypes. Evaluation of the functional effects of this series on second messenger responses in cells expressing human mGlu2 or mGlu3 receptors revealed C3beta-methyl analogue 5 to possess antagonist properties at both mGlu2 and mGlu3 receptors while C4beta-methyl analogue 9 acts as a full agonist at each of these targets. Unexpectedly, we found that incorporation of a methyl substituent at the C4alpha-position as in analogue 13 results in a mixed mGlu2 agonist/mGlu3 antagonist pharmacological profile. All of the mGlu2 agonist and mGlu3 antagonist activity of rac-13 was found to reside in its resolved (+)-isomer.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15887967 DOI: 10.1021/jm040222y
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446